Inovio Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Inovio Pharmaceuticals Inc cash flow-to-debt ratio. Inovio Pharmaceuticals Inc (INO) has a Cash Flow-to-Debt Ratio of -0.28x as of September 2025, meaning its operating cash flow of $-21.57 Million could theoretically repay 0% of its total liabilities ($77.11 Million) in one year. Check Inovio Pharmaceuticals Inc (INO) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Inovio Pharmaceuticals Inc (1998–2024)
Cash flow-to-debt ratio of Inovio Pharmaceuticals Inc from 1998 to 2024. Historical debt coverage capacity for Inovio Pharmaceuticals Inc across 27 annual periods. Check Inovio Pharmaceuticals Inc (INO) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Inovio Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (1998–2024)
Inovio Pharmaceuticals Inc cash flow-to-debt ratio by year from 1998 to 2024. Year-by-year debt coverage analysis for Inovio Pharmaceuticals Inc. For the full cash flow conversion analysis, see Inovio Pharmaceuticals Inc cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.33x | $-104.08 Million | $44.69 Million | ▼ -0.4% |
| 2023 | -2.32x | $-124.37 Million | $53.60 Million | ▼ -35.4% |
| 2022 | -1.71x | $-216.22 Million | $126.17 Million | ▲ +23.5% |
| 2021 | -2.24x | $-215.71 Million | $96.27 Million | ▲ +1.0% |
| 2020 | -2.26x | $-177.98 Million | $78.63 Million | ▼ -220.5% |
| 2019 | -0.71x | $-97.85 Million | $138.55 Million | ▲ +57.7% |
| 2018 | -1.67x | $-73.55 Million | $44.08 Million | ▼ -18.1% |
| 2017 | -1.41x | $-63.21 Million | $44.75 Million | ▼ -13.6% |
| 2016 | -1.24x | $-62.56 Million | $50.33 Million | ▼ -278.8% |
| 2015 | -0.33x | $-12.44 Million | $37.91 Million | ▲ +77.7% |
| 2014 | -1.47x | $-29.82 Million | $20.25 Million | ▼ -238.8% |
| 2013 | -0.43x | $-15.38 Million | $35.38 Million | ▲ +80.0% |
| 2012 | -2.17x | $-22.31 Million | $10.28 Million | ▼ -45.5% |
| 2011 | -1.49x | $-19.76 Million | $13.24 Million | ▼ -12.0% |
| 2010 | -1.33x | $-11.94 Million | $8.97 Million | ▼ -83.9% |
| 2009 | -0.72x | $-14.08 Million | $19.44 Million | ▼ -29.4% |
| 2008 | -0.56x | $-11.13 Million | $19.88 Million | ▲ +57.5% |
| 2007 | -1.32x | $-11.51 Million | $8.74 Million | ▼ -132.8% |
| 2006 | -0.57x | $-7.04 Million | $12.45 Million | ▲ +74.7% |
| 2005 | -2.24x | $-12.34 Million | $5.51 Million | ▼ -77.9% |
| 2004 | -1.26x | $-6.80 Million | $5.40 Million | ▲ +45.9% |
| 2003 | -2.33x | $-2.75 Million | $1.18 Million | ▲ +20.5% |
| 2002 | -2.93x | $-4.96 Million | $1.69 Million | ▲ +41.6% |
| 2001 | -5.01x | $-8.37 Million | $1.67 Million | ▲ +9.0% |
| 2000 | -5.51x | $-8.79 Million | $1.60 Million | ▼ -90.7% |
| 1999 | -2.89x | $-6.30 Million | $2.18 Million | ▲ +31.2% |
| 1998 | -4.20x | $-6.30 Million | $1.50 Million | — |